Status:

COMPLETED

Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study

Lead Sponsor:

Mayo Clinic

Conditions:

Breast Carcinoma

Digestive System Neoplasm

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

This phase I trial collects blood samples to investigate the prevalence of changes in genes (genetic mutations) in solid tumor patient populations seeking care at Mayo Clinic Embedded Cancer Center at...

Detailed Description

PRIMARY OBJECTIVE: I. To determine the prevalence of genetic mutations in cancer patients seeking care at the Mayo Clinic Cancer Center at St. Vincent's Riverside in Jacksonville, Florida. SECONDARY...

Eligibility Criteria

Inclusion

  • Individuals diagnosed with any solid tumor cancer (stages 1-4) including, but not limited to, gastrointestinal, breast, gynecological, genitourinary, skin, central nervous system (CNS)/brain, head/neck, musculoskeletal or cancer of unknown primary
  • Blood collection is feasible (health, access and/or tolerability) for requested blood sample(s)
  • Individuals have agreed to participate and signed the study informed consent form

Exclusion

  • Individuals who do not meet study inclusion criteria
  • Individuals with an active hematologic malignancy
  • Patients who have had prior germline genetic testing involving a 40+ gene panel within the last 24 months at Mayo Clinic or St Vincent's Healthcare and available for review by the research coordinator at time of consent

Key Trial Info

Start Date :

June 29 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 21 2021

Estimated Enrollment :

230 Patients enrolled

Trial Details

Trial ID

NCT04456140

Start Date

June 29 2020

End Date

September 21 2021

Last Update

July 24 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Mayo Clinic in Arizona

Scottsdale, Arizona, United States, 85259

2

Mayo Clinic in Florida

Jacksonville, Florida, United States, 32224-9980